Targeting of melanoma brain metastases using engineered neural stem/progenitor cells

133Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases. Copyright © 2006 by the Society for Neuro-Oncology.

Cite

CITATION STYLE

APA

Aboody, K. S., Najbauer, J., Schmidt, N. O., Yang, W., Wu, J. K., Zhuge, Y., … Perides, G. (2006). Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-Oncology, 8(2), 119–126. https://doi.org/10.1215/15228517-2005-012

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free